Could a new sedative keep seniors Clear-Headed after cancer surgery?
NCT ID NCT07351474
First seen Jan 25, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This study tests whether remimazolam, a newer anesthetic, can reduce the risk of postoperative delirium (sudden confusion) in elderly patients undergoing laparoscopic stomach cancer surgery. Researchers will compare remimazolam to standard anesthesia in 170 patients aged 65 and older. The goal is to see if this drug leads to better recovery and fewer cognitive issues after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Remimazolam
What this could lead to
If successful, this could point toward a safer anesthetic option for elderly patients, potentially reducing confusion and cognitive decline after major surgery.
What could go wrong
This is a small, early-stage trial (170 participants) that has not yet started recruiting. The results may not apply to all patients, and remimazolam may not prove better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.